[PDF] Top 20 Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Has 10000 "Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy" found on our website. Below are the top 20 most common "Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy".
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
... therapy versus indefinite pemetrexed maintenance therapy alone. At disease progression, those patients in the peme- trexed alone group were allowed for crossover to receive pembrolizumab. The primary endpoint was ... See full document
8
<p>The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy</p>
... years, immunotherapy targeting immune checkpoints has shed a light on cancer ...of cancer treatment by inhibiting the immune checkpoint programmed cell death protein 1 (PD-1) and ... See full document
9
Targeting PD-1/PD-L1 in lung cancer: current perspectives
... the development of effective immunotherapy ...of antibodies against immune checkpoint inhibitors. Anti-PD-1/ PD-L1 antibodies are currently in advanced phases of ... See full document
16
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
... and PD-L1 expression cut-off thresholds, sampling for PD-L1 expression on metastatic lesions ...subsequent immunotherapy in the standard of care arms, and outperformance or over- ... See full document
18
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
... of PD-1 positive (+) TILs in cancer ...of PD-1(+) TILs were significantly associated with prolonged disease-free survival of pulmonary squamous cell carcinoma (SqCC) patients ...of ... See full document
12
PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer
... of cancer [7]. As for immune escape of cancer cells, the identification of PD-1 (programmed death 1) and PD-L1 (programmed death-ligand 1) axis was one of the most ... See full document
9
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
... community. PD-L1, typically expressed on the surface of healthy cells, binds PD-1 on primed cytotoxic T cells thereby inhibiting cell-mediated attack ...ing PD-L1 [2, ... See full document
6
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
... targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 ...However, PD-1/PD-L1 ... See full document
13
Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials
... to 1 May 2017 (online supplementary file ...Lung Cancer World Conference on Lung Cancer annual meeting and European Society of Medical Oncology annual meeting were also searched from 2012 to 2017 for ... See full document
11
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
... and clinical response in pa- tients [28, ...the PD-1/PD-L1 axis molecules, the local TME may be a key site for identifying predictive biomarkers for PD-1 pathway ...of ... See full document
25
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
... the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of ...cancers. PD-L1 is constitutively expressed in certain tumors and host ... See full document
8
From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
... bladder cancer, but are associated with clinically significant toxicities, including myelosup- pression, ototoxicity, neurotoxicity, and nephrotoxicity [3 – ... See full document
15
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
... multiple cancer types and provides promising clinical responses, durable disease control, and fewer adverse events among patients with advanced melanoma, non- small cell lung cancer (NSCLC), and ... See full document
8
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
... and clinical outcome, low complexity, high re- producibility, low cost, and ease of standardization ...Only recent clinical research has looked at specific bio- markers to serve as a basis for ... See full document
13
Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
... TCGA also recently reported the genomic characterisation of oesophageal carcinoma (22). As one would expect, squamous cell carcinoma (SCC) and adenocarcinoma were molecularly distinct. Oesophageal adenocarcinoma strongly ... See full document
42
Clinical applications of PD-L1 bioassays for cancer immunotherapy
... examined PD-L1 expression with the SP142 IHC assay in both whole surgical tissue sections and matched lung biopsies from 160 patients with operable ...NSCLC. PD-L1 expression was assayed in ... See full document
6
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
... IHC antibodies, interpretations (expression on tumor cells, immune cells or both) and thresholds for ...for PD-L1 positivity using four different PD-L1 IHC assays, 22C3, 28-8, SP263 and ... See full document
12
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1
... the development of the immune system, especially for the selection of T-cells with appropriate ...gravis. Immunotherapy may be a promising option for the treatment of advanced refractory TET (Thymic ... See full document
12
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy
... death 1 (PD-1) receptor, an immune checkpoint expressed on exhausted effector T lymphocytes, and prevents binding by its activating ligand PD-L1, leading to reinvigoration of anti-tumor ... See full document
7
<p>A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer</p>
... of PD-1/PD-L1 drugs targeting bladder carcinoma have not been conducted, most of the included studies were completed phase I/II/III randomized single-arm trials, and potential performance bias ... See full document
11
Related subjects